Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

EN
  • 中文
  • 繁体
  • EN
    • Related Links
    ESG Practice and Honor
    Home  >  ESG  >  ESG Practice and Honor
    ESG Management ESG Practice and Honor ESG Reports
    Our Performance
    • 77.3 %
      The proportion of revenue from innovative drugs and cooperative products to total revenue in 2024
    • 50 %
      Percentage of female directors reached 50%
    • 25.96 %
      Progress of greenhouse gas emission reduction targets: The emissions of greenhouse gas per unit revenue 2023 (scope I and scope II) reduced by 25.96% than that in 2021
    • 85 % +
      Employee satisfaction rate of 85.5%
    • 92523 person-times
      Hansoh Pharma provided quality related trainingfor a total of 92,523 person-times
    • 28.17 %
      Progress of emission reduction of exhaust pollutants: Total emissions of VOCs in exhaust reduced by 28.17% than that in 2021
    • 100 %
      100% approval rate for product certification checks and customer audits
    • 37
      As of the end of 2023，the number of drugs had entered 37 low- and middle-income countries and regions
    • MORE
    ESG Recognitions and Awards
    • MSCI ESG rating scored AA
    • Included in the “S&P Global Sustainability Yearbook (China) 2024”，ranking in the Top 1% for its S&P Global CSA Score（69）in 2023
    • Included in the “S&P Global Sustainability Yearbook 2024”, outperformed other Chinese pharmaceutical companies in terms of CSA Score (69) in 2023
    • Included in the first “Sustainability Yearbook (China)” published by S&P Global, ranking in the Top 1% for its S&P Global ESG score and gained recognition as an “Industry Mover”.
    • Included in the S&P GlobalSustainability Yearbook 2023, the only pharmaceuticalcompanv in China Mainland to be selected
    • The Asset ESG Corporate Awards 2023—GoldAward
    • The Best Industrial Enterprise of Pharmaceutical R&D Product Line in China
    • AAA Credit Rating of Pharmaceutical Industry Enterprises
    • Typical Case of National Intellectual Property Right Demonstration Enterprises
    • Jiangsu Science and Technology Innovation and Development Award
    • ESG Leading Enterprise Awards 2022 organized by Bloomberg Businessweek/Chinese Edition
    • S&P CSA score is significantly improved
    • Named to HRoot's "Excellent Employers in Greater China 2022" List
    • Named to "ESG Competence of China's Listed Pharmaceutical Companies 2022" List
    • Named to "Excellent CSR Programs of China's Pharmaceutical Companies" List
    • Named to "Good CSR Performers in Pudong New Area" List
    • Changzhou Hansoh Pharmaceutical has obtained its first ISO 50001 Energy Management System certification
    • Hansoh Pharma's all production sites obtained the Energy and Environmental Management Systems certification
    • 2020 ESG report won “AA” rating by International Forum on Social Responsibilities of Industrial and Information Enterprises